Loading...

Nirvana Life Sciences Inc.

NIRV.CNCNQ
Healthcare
Biotechnology
CA$0.08
CA$-0.02(-20.00%)

Nirvana Life Sciences Inc. (NIRV.CN) Stock Competitors & Peer Comparison

See (NIRV.CN) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
NIRV.CNCA$0.08-20.00%385.9K-0.40-CA$0.20N/A
BLU.TOCA$19.48-0.10%2.5B-20.29-CA$0.96N/A
MMED.NECA$14.90+9.48%1.1B-4.50-CA$3.31N/A
DRUG.CNCA$58.56-2.43%414.8M-42.74-CA$1.37N/A
FRX.TOCA$11.94+4.28%328.1M-19.26-CA$0.62N/A
EPRX.TOCA$7.33+1.81%262.6M-6.16-CA$1.19N/A
CYBN.NECA$9.76+1.67%226.8M-1.60-CA$6.15N/A
ONC.TOCA$1.42+2.16%142.3M-3.84-CA$0.37N/A
MSCL.TOCA$0.59+1.72%103.9M2.27CA$0.26N/A
HBP.TOCA$1.35+0.00%100.1M-1.31-CA$1.03N/A
Showing 1 to 10 of 59 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

NIRV.CN vs BLU.TO Comparison August 2025

NIRV.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NIRV.CN stands at 385.9K. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, NIRV.CN is priced at CA$0.08, while BLU.TO trades at CA$19.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NIRV.CN currently has a P/E ratio of -0.40, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, NIRV.CN's ROE is +0.00%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, NIRV.CN is more volatile compared to BLU.TO. This indicates potentially higher risk in terms of short-term price fluctuations for NIRV.CN.Check BLU.TO's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;